News
Representing Methazolamide
Methazolamide (Generic: Neptazane) was approved by the FDA on August 28, 1996 and is manufactured by Wyeth-Ayerst.
Methazolamide is prescribed to treat glaucoma, certain kinds of tremors, and mountain or altitude sickness. Methazolamide is a carbonic anhydrase inhibitor. Carbonic anhydrase is a protein in the body, and Methazolamide reduces its activity. In treating glaucoma, Methazolamide reduces the actions of carbonic anhydrase and the amount of fluid produced in the eyes, which also reduces pressure.
There have been instances of people taking Methazolamide developing Stevens Johnson Syndrome (SJS), a rare skin disease. Stevens Johnson Syndrome can cause rash, skin peeling, and sores on the mucous membranes. Stevens Johnson Syndrome is an immune-complex–mediated hypersensitivity disorder that may be caused by many drugs, viral infections, and malignancies. SJS patients are often treated in burn centers due to their open wounds and risk of infection. SJS can be fatal. Many drugs that cause the onset of Stevens Johnson Syndrome did not have warnings placed on their labels until recently.